Abiopharma

🔍 KASINGER JAMES R. (Executive)

Company: CRISPR Therapeutics AG (CRSP)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 5,500 shares of Common Shares (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: false | shares_owned_after: 90,615.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,800 shares of Common Shares at $52.8 per share (Direct)
  Date: 2026-03-11 | Code: S | equity_swap_involved: false | shares_owned_after: 87,815.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 5,500 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-10 | Code: M | equity_swap_involved: false | shares_owned_after: 5,500.00 | transaction_form_type: 4 | Footnotes: F2, F1, F2, F4, F4

Footnotes:

• F1: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
• F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
• F3: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
• F4: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.